Edition:
United States

Imprimis Pharmaceuticals Inc (IMMY.OQ)

IMMY.OQ on NASDAQ Stock Exchange Capital Market

1.74USD
16 Feb 2018
Change (% chg)

$0.00 (+0.29%)
Prev Close
$1.73
Open
$1.75
Day's High
$1.79
Day's Low
$1.72
Volume
21,886
Avg. Vol
128,449
52-wk High
$4.68
52-wk Low
$1.35

Select another date:

Tue, Jan 30 2018

BRIEF-Imprimis Pharma Makes Available Two Glaucoma Drugs On FDA's Drug Shortage List

* IMPRIMIS PHARMACEUTICALS NOW MAKING AVAILABLE TWO GLAUCOMA DRUGS ON FDA'S DRUG SHORTAGE LIST Source text for Eikon: Further company coverage:

BRIEF-Imprimis Pharmaceuticals Is Issued DEA Manufacturer Certificate For Its 503B Outsourcing Facility

* IMPRIMIS PHARMACEUTICALS IS ISSUED DEA MANUFACTURER CERTIFICATE FOR ITS 503B OUTSOURCING FACILITY Source text for Eikon: Further company coverage:

Imprimis receives FDA warning over eye medication advertising

Jan 16 The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval.

Allergan may pursue lawsuit against drug compounder Imprimis

Allergan PLC can proceed with a false advertising lawsuit seeking to stop Imprimis Pharmaceuticals Inc from selling compounded drugs that bypass regulatory approval, including a cheaper alternative to Allergan's dry eye drug, Restasis, a federal judge has ruled.

BRIEF-Imprimis Pharmaceuticals Q3 loss per share $‍0.28​

* Imprimis Pharmaceuticals announces third quarter 2017 results

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

UPDATE 3-Imprimis Pharma to take on Allergan's Restasis with cheaper product

Oct 19 Shares of Imprimis Pharmaceuticals Inc sky-rocketed as much as 91 percent on Thursday, after the company said it would launch a cheaper alternative to Allergan Plc's controversial dry eye drug, Restasis, by next month.

BRIEF-Imprimis Pharma CEO says company intends to start selling prescriptions for its cheaper alternative to Restasis on Nov 1‍​

* CEO - Intends to start selling prescriptions for its cheaper alternative to Restasis on November 1‍​ Further company coverage:

Imprimis Pharma to take on Allergan's Restasis with cheaper product

Oct 19 Shares of Imprimis Pharmaceuticals sky-rocketed as much as 91.1 percent on Thursday, after it said it would offer a cheaper option to Allergan's dry eye disease medicine, Restasis.

BRIEF-Imprimis Pharmaceuticals to offer compounded Cyclosporine alternative to Restasis

* Imprimis Pharmaceuticals-‍making compounded Cyclosporine-based formulations available for physicians to consider prescribing as alternatives to Restasis​ Source text for Eikon: Further company coverage:

Select another date: